Allurion Technologies, Inc.

Allurion Technologies, Inc. is a medical device company dedicated to addressing obesity through its comprehensive weight loss platform. Founded in 2009 by Dr. Shantanu Gaur and Samuel Levy, the company's mission is to end obesity. Its headquarters are located in Natick, Massachusetts, USA.

The core of Allurion's offering is the Allurion Program, which features the Allurion Gastric Balloon System (also known as the Allurion Smart Capsule or Allurion Balloon). This innovative device is a swallowable, procedure-less intragastric balloon designed for weight loss, eliminating the need for surgery, endoscopy, or anesthesia for placement or removal. The program integrates this device with the Allurion Virtual Care Suite, a digital platform comprising the Allurion Mobile App for consumers, Allurion Insights for clinicians (powered by the Iris AI platform), and connected scale and health tracker devices.

In recent news, Allurion Technologies received U.S. FDA approval for its Allurion Gastric Balloon System on February 23, 2026, opening access to an estimated 80 million Americans. Following this approval, the company began training U.S. accounts and manufacturing FDA-approved products in March 2026, with shipping anticipated in April 2026. Allurion is positioned as a pioneer in metabolically healthy weight loss, offering an alternative or complement to GLP-1 medications and bariatric surgery. Dr. Shantanu Gaur serves as the Chief Executive Officer and Co-Founder. The company also announced a partnership in February 2026 to offer combination therapy with Mounjaro (tirzepatide) at discounted prices. Allurion is publicly traded on the New York Stock Exchange under the ticker ALUR.